Literature DB >> 20104262

Ginsenoside Rg3 Suppresses Palmitate-Induced Apoptosis in MIN6N8 Pancreatic beta-Cells.

Kyong Kim1, Min Park, Hye Young Kim.   

Abstract

Chronic exposure to elevated levels of free fatty acids (FFA) causes beta-cell dysfunction and may induce beta-cell apoptosis in type 2 diabetes. The execution of beta-cell apoptosis occurs through activation of mitogen-activated protein kinases (MAPKs). Ginsenoside Rg3 (Rg3), one of the active ingredients of ginseng saponins, has not been known about the effects on beta-cell apoptosis mediated with FFA. The aims of this study were to investigate the in vitro protective effects of Rg3 on MIN6N8 mouse insulinoma beta-cells against FFA-induced apoptosis, as well as the modulating effects on p44/42 MAPK activation. Our results showed that Rg3 inhibited the palmitate-induced apoptosis through modulating p44/42 MAPK activation. We conclude that Rg3 has the potential role in suppressing the progression of type 2 diabetes by inhibiting FFA-mediated loss of beta-cells.

Entities:  

Keywords:  MIN6N8 cells; apoptosis; ginsenoside Rg3; p44/42 MAPK; palmitate

Year:  2009        PMID: 20104262      PMCID: PMC2803130          DOI: 10.3164/jcbn.09-49

Source DB:  PubMed          Journal:  J Clin Biochem Nutr        ISSN: 0912-0009            Impact factor:   3.114


Introduction

Increased free fatty acids (FFA), alone or in conjunction with hyperglycemia, have been proposed to trigger β-cell loss in type 2 diabetes [1] and moreover, in vitro studies have demonstrated that long-term exposure to FFA can induce β-cell death in culture and in isolated islets [2]. The death was mainly apoptotic with cytochrome c release, caspase-3 activation, and DNA fragmentation [2-4]. Especially, saturated fatty acids like palmitic and stearic acids, were found to be generally cytotoxic to β-cells, whereas unsaturated fatty acids like linoleic, oleic, and palmitoleic acids, were not, and even protected cells from saturated FFA-induced apoptosis [5]. Cells recognize and respond to extracellular stimuli by engaging specific intracellular programs, such as the signaling cascade that leads to activation of the mitogen-activated protein kinases (MAPKs) [6]. P44/42 MAPK or extracellular-regulated protein kinases (ERK), one of MAPK family, is generally activated by mitogens and survival factors [7]. Therefore, selective activation of p44/42 can prevent apoptosis and ensures cell survival in several cell systems [7]. It should be emphasized, however, that the anti-apoptotic role of p44/42 MAPK is not absolute. Ginseng (the root of Panax ginseng C.A. Meyer, family Aralianceae) has been used clinically to treat type 2 diabetes [8-9] and has also been used as a tonic, often taken for years without evidence of adverse effects or toxicity [10-11]. In recent years, accumulating evidence in vitro and in vivo has shown that ginseng and its extracts possess anti-diabetic activities [12-16]. The effects of ginseng might be attributable to its major ginsenoside constituents. However, little information is available about the effect of ginsenoside Rg3 (20-S-protopanaxadiol-3-[O-β-D-glucopyranosyl (1→2)-β-glucopyranoside]) (Rg3) on FFA-induced apoptosis in β-cells. This study was designed to investigate whether Rg3 could mediate protective effects against palmitate-induced apoptosis, and whether Rg3 could modulate p44/42 MAPK activation in MIN6N8 mouse insulinoma β-cells.

Materials and Methods

Cell cultures and palmitate treatment

As a model of pancreatic β-cells, SV40 T-transformed insulinoma cells derived from nonobese diabetic (NOD) mice were used (MIN6N8). The cells were kindly provided by Prof. Myung-Shik Lee (Sungkyunkwan University School of Medicine, Seoul, Korea) under the permission of Prof. Junichi Miyazaki (Osaka University, Osaka, Japan) [17]. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 15% fetal bovine serum, 2 mM glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Reagents were obtained from the following sources: high glucose DMEM, FBS, trypsin-EDTA 100 IU/ml, penicillin and 100 µg/ml streptomycin from Gibco (Grand Island, NY). Sodium carbonate, β-mercaptoethanol, and sodium palmitate from Sigma-Aldrich Corp. (St. Louis, MO). Palmitate-mediated apoptosis was induced by incubation with 500 µM palmitate for 48 h. The choice of palmitate concentration and incubation time was based on the preliminary study.

Rg3 administration

Rg3 was purchased from Fleton Reference Substance Co., Ltd (Huaishu, Chengdu, China). Rg3 was administrated simultaneously with palmitate.

Cell viability assay

Cell viability was determined by the reduction of yellow 3-(4,5-dimethylthaizol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma) into a purple formazane product by mitochondrial dehydrogenase of metabolically active cells. Briefly, cells were seeded at a density of 2 × 106 cells/well into 96-well plate. After overnight growth, cells were treated with palmitate and Rg3 for 48 h. The final concentrations of DMSO in the culture medium were <0.1%. At the end of treatment, 30 µl of MTT was added, and cells were incubated for a further 4 h. Cell viability was obtained by scanning with an Enzyme-Linked Immunosorbent Assay (ELISA) reader with a 570 nm filter [18].

Apoptosis assay

For quantitative determination of apoptotic cell death, cytoplasmic histone-associated DNA fragments were measured with the Cell Death Detection ELISA kit from Roche (Mannheim, Germany) according to the manufacture’s instructions. This assay is based on a quantitative sandwich enzyme immunoassay principle, using mouse monoclonal antibodies directed against DNA and histones. This allows the specific determination of mono- and oligonucleosomes but not free histone or DNA that may generate during nonapoptotic cell death [19] in the cytoplasmic fraction of cell lysates. At the end of the culture period, cells were washed with phosphate-buffered saline (PBS), lysed according to the manufacturer’s protocol, centrifuged (200 × g, 10 min), placed in a streptavidin-coated microtiter plate, and incubated with a mixture of antihistone (biotin-labeled) and anti-DNA (conjugated with peroxidase) antibodies. After removal of the unbound antibodies by a washing step, the amount of nucleosomes was quantified photometrically by the peroxidase retained in the immunocomplex.

Preparation of cell lysates and immunoblotting

Treated cells were harvested after centrifugation at 4°C, then washed with ice-cold PBS, and immediately lysed in lysis buffer (cellLytic MT Mammalian Tissue lysis/extraction reagent, Sigma) for 30-min vortex at 4°C. After centrifugation at 13,000 × g at 4°C for 20 min to separate the cellular debris, the supernatant was collected and stored at −70°C until use. The protein concentrations were determined using an assay kit for protein determination (Quick Start Bradford Dye Reagent; Bio-Rad Laboratories, Richmond, CA) according to the manufacturer’s instructions. SDS-PAGE was performed in 10% polyacrylamide gels loading equal amount of proteins per lane. Proteins were then transferred to immunoblot PVDF membranes (Bio-Rad) in Tris-borate-EDTA buffer at 100 V for 1 h. The membrane was blocked with 5% non-fat milk in TBST buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 0.01% Tween 20) for 1 h. Membranes were incubated for 4 h at room temperature with primary antibodies (diluted 1:200–1:1000). The antibodies against polyclonal p-44/42 MAPK and phosphorylated p-44/42 MAPK was purchased from Cell Signaling Technology (Beverly, MA). The antibodies against cleaved PARP and β-actin was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Secondary antibodies were obtained from Vector Laboratories (Burlingame, CA); horseradish peroxidase-conjugated anti goat or anti rabbit, and exposed to an enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech., Piscataway, NJ). Immunoblots were analyzed with a GS-800 calibrated densitometer (Bio-Rad).

Statistical analyses

Experiments were performed in triplicate and replicated three times. All values were expressed as mean and standard deviations (S.D.). One-way analysis of variance (ANOVA) followed by Duncan’s multiple range test were used for statistical analyses (SAS software, SAS Inc., Cary, NC).

Results

Ginsenoside Rg3 attenuated palmitate-induced cytotoxicity in MIN6N8 cells

We first examined the effects of Rg3 on the cell viability of MIN6N8 cells using the MTT assay. Cells treated with 500 µM palmitate for 48 h reduced cell viability by approximately 50% relative to the palmitate-untreated cells. This cytotoxic effect was attenuated by co-treatment with Rg3 in 1–5 µM in part dose-dependently (Fig. 1A). Palmitate-untreated cells administered with 1–5 µM Rg3 showed no difference on cell viability from that of the palmitate-untreated control cells (not shown in data).
Fig. 1

(A) Effect of ginsenoside Rg3 on cell viability in palmitate-treated MIN6N8 cells. The cells were treated with 500 µM palmitate in the presence or absence of 1–5 µM Rg3 for 48 h. Cell viability was determined by MTT assay. Values are means ± SD (n = 9). Means with different letters differ significantly among groups (p<0.05). (B) Effect of Rg3 on palmitate-induced apoptosis in MIN6N8 cells. The cells were treated with Rg3 simultaneously with palmitate for 48 h. Apoptosis was determined as the amount of cytosolic histone-associated DNA fragments. Values are means ± SD (n = 9). Means with different letters differ significantly among groups (p<0.05).

Ginsenoside Rg3 reduced palmitate-induced apoptosis

Next, we measured nucleosomal release as an early biochemical feature and quantitative marker of apoptosis [20]. Incubating the cells with 500 µM palmitate resulted in an enrichment of mono- and oligonucleosomes in the cytoplasm due to the DNA degradation by 4.3 fold compared to palmitate-untreated control (Fig. 1B). The palmitate-mediated nucleosomal release was significantly inhibited by the co-treatment with Rg3 at the concentration of 1–5 µM in part dose-dependently (Fig. 1B).

Ginsenoside Rg3 suppressed palmitate-induced cleavage of PARP

To investigate the underlying mechanisms for protection by Rg3 against palmitate-induced apoptosis, we analyzed whether poly (ADP-ribose) polymerase (PARP) were involved in this process. PARP (116 kDa) is cleaved to produce an 89 kDa fragment during apoptosis. When MIN6N8 cells were incubated with 500 µM palmitate for 48 h, PARP cleavage, as evidenced by accumulation of 89 kDa species, was noted (Fig. 2A). The activation of PARP was significantly recovered by co-treatment with Rg3 at 0.1–5.0 µM (Fig. 2).
Fig. 2

Effect of ginsenoside Rg3 on palmitate-induced cleavage of PARP in MIN6N8 cells. Cells were incubated with 500 µM palmitate in the presence or absence of Rg3 (0.1–5.0 µM) for 48 h. Cell lysates were subjected to Western blot analysis for cleaved PARP and β-actin. (A) Results are representative of three independent experiments. (B) Density ratio of cleaved PARP/β-actin. Means with different letters differ significantly among groups (p<0.05).

Ginsenoside Rg3 suppressed palmitate-induced activation of p44/42 MAPK

When MIN6N8 cells were incubated with 500 µM palmitate and analyzed over a 48-h, p44/42 MAPK activation, as evidenced by phosphorylation of what appeared to be two isoforms, was noted at 48 h after administration with palmitate (Fig. 3A). To explore the involvement of p44/42 MAPK in the mechanism of protection by Rg3, we examined the effects of Rg3 on palmitate-mediated p44/42 MAPK activation. Based on the results of Western blot, it was found that co-treatment of the cells with Rg3 (0.1–5.0 µM) suppressed palmitate-induced phosphorylation of p44/42 MAPK (Fig. 3B).
Fig. 3

Effect of ginsenoside Rg3 on palmitate-induced activation of p44/42 MAPK in MIN6N8 cells. (A) Time course of p44/42 activation with palmitate exposure to MIN6N8 cells. The cells were administrated with 500 µM palmitate for the indicated time points and harvested for whole-cell lysates to be used in Western blots. Total p44/42 was probed as well. All data are representative of three independent experiments. (B) Effect of Rg3 on palmitate-induced phosphorylation of p44/42 in the cells. The cells were treated with palmitate in the presence or absence of Rg3 for 48 h, and Western blot analysis was performed. All data are representative of three independent experiments.

Discussion

FFA have been shown to promote a pro-apoptotic effect on β-cells [21] that may explain, at least partially, the elevated rates of β-cell apoptosis and reduction in β-cell mass seen in diabetes [22]. FFA can affect β-cell apoptosis directly through the influence on modulating multiple intracellular signaling pathways, or remotely through cytokines that are secreted by adipose tissues-adipokines [23]. Apoptosis is a highly regulated death process which is predominant mode of cell death induced by palmitate in pancreatic β-cells [24]. The data that we obtained with MIN6N8 cells indicating that palmitate inhibited the proliferation of the cells, induced an increase of the histone-associated DNA fragments, and cleaved PARP, are in agreement with an earlier study using the MIN6N8a cells [24]. In the present study, we demonstrated for the first time that Rg3 protected MIN6N8 pancreatic β-cells against palmitate-induced apoptotic cell death. PARP is a DNA repair enzyme that can be activated by DNA strand breaks [25]. The cleavage of full-length PARP (116 kDa) to cleaved PARP (89 kDa) serves as a marker of cell apoptosis [26]. Our study indicated that Rg3-treatment blocked the cleavage of PARP caused by palmitate in MIN6N8 cells. Our results suggest that the anti-apoptotic effect of Rg3 involves the suppression of PARP cleavage. In contrast to stress-activated protein kinase/c-Jun N-terminal kinases (SAPK/JNK) and p38, p44/42 MAPK is usually associated with differentiation and proliferation in many mammalian cells, including β-cells [27]. P44/42 activity, relative to SAPK/JNK and p38, was unaffected throughout the stressful procedure for pancreatic islet transplantation [28]. Meanwhile, several studies show that the cytotoxic effects of human islet amyloid polypeptide on rat insulinoma cell lines RINm5F and INS-1E were mediated by activation of multiple MAPK pathways including p44/42 [29-31]. Interleukin (IL)-1β, an inflammatory cytokine, induces cell death via activating MAPKs, including SAPK/JNK, p38 and p44/42 [32]. Interestingly, we showed that palmitate activated p44/42 MAPK in MIN6N8 cells, and that co-treatment of Rg3 with palmitate suppressed p44/42 MAPK activation. Our result suggests that palmitate-induced apoptosis involves the activation of p44/42 MAPK and that the anti-apoptotic effect of Rg3 involves the suppression of p44/42 activation. In conclusion, the present study suggests that Rg3 protects MIN6N8 pancreatic β-cells against palmitate-induced apoptosis in part through suppressing PARP cleavage and p44/42 activation. The results supports the potential role of Rg3 in suppressing the progression of type 2 diabetes by inhibiting FFA-mediated loss of pancreatic β-cells.
  28 in total

Review 1.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

2.  Ginsenoside 20S-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor gamma (PPARgamma) in 3T3-L1 adipocytes.

Authors:  Kyu Lee Han; Myeong Ho Jung; Jong Hee Sohn; Jae-Kwan Hwang
Journal:  Biol Pharm Bull       Date:  2006-01       Impact factor: 2.233

Review 3.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 4.  Morphological and biochemical characterization and analysis of apoptosis.

Authors:  R T Allen; W J Hunter; D K Agrawal
Journal:  J Pharmacol Toxicol Methods       Date:  1997-06       Impact factor: 1.950

5.  Ginseng therapy in non-insulin-dependent diabetic patients.

Authors:  E A Sotaniemi; E Haapakoski; A Rautio
Journal:  Diabetes Care       Date:  1995-10       Impact factor: 19.112

6.  Amylin-induced cytotoxicity is associated with activation of caspase-3 and MAP kinases.

Authors:  Lada Rumora; Mirko Hadzija; Karmela Barisić; Dusica Maysinger; Tihana Zanić Grubiić
Journal:  Biol Chem       Date:  2002-11       Impact factor: 3.915

7.  Anti-hyperglycemic effects of ginseng: comparison between root and berry.

Authors:  L Dey; J T Xie; A Wang; J Wu; S A Maleckar; C S Yuan
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

8.  Phycocyanin protects INS-1E pancreatic beta cells against human islet amyloid polypeptide-induced apoptosis through attenuating oxidative stress and modulating JNK and p38 mitogen-activated protein kinase pathways.

Authors:  Xiao-Ling Li; Gang Xu; Tianfeng Chen; Yum-Shing Wong; Hai-Lu Zhao; Rong-Rong Fan; Xue-Mei Gu; Peter C Y Tong; Juliana C N Chan
Journal:  Int J Biochem Cell Biol       Date:  2009-01-08       Impact factor: 5.085

9.  Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes.

Authors:  N Yagi; K Yokono; K Amano; M Nagata; K Tsukamoto; Y Hasegawa; R Yoneda; N Okamoto; H Moriyama; M Miki
Journal:  Diabetes       Date:  1995-07       Impact factor: 9.461

10.  Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

Authors:  Roberto Lupi; Francesco Dotta; Lorella Marselli; Silvia Del Guerra; Matilde Masini; Carmela Santangelo; Giovanni Patané; Ugo Boggi; Salvatore Piro; Marcello Anello; Ettore Bergamini; Franco Mosca; Umberto Di Mario; Stefano Del Prato; Piero Marchetti
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

View more
  8 in total

1.  Ginsenoside Rg3 prevents INS-1 cell death from intermittent high glucose stress.

Authors:  You Jeong Kim; Su Min Park; Hye Sook Jung; Eun Ju Lee; Tae Kyoon Kim; Tae-Nyun Kim; Min Jeong Kwon; Soon Hee Lee; Byoung Doo Rhee; Mi-Kyung Kim; Jeong Hyun Park
Journal:  Islets       Date:  2016-04-18       Impact factor: 2.694

2.  Saturated free fatty acids induce cholangiocyte lipoapoptosis.

Authors:  Sathish Kumar Natarajan; Sally A Ingham; Ashley M Mohr; Cody J Wehrkamp; Anuttoma Ray; Sohini Roy; Sophie C Cazanave; Mary Anne Phillippi; Justin L Mott
Journal:  Hepatology       Date:  2014-06-20       Impact factor: 17.425

3.  Ginsenoside Rg3 enhances the inhibitory effects of chemotherapy on esophageal squamous cell carcinoma in mice.

Authors:  Liang Chang; Bingjie Huo; Yalei Lv; Yudong Wang; Wei Liu
Journal:  Mol Clin Oncol       Date:  2014-07-23

4.  EFFECTS OF GINSENG AND ITS FOUR PURIFED GINSENOSIDES (Rb2, Re, Rg1, Rd) ON HUMAN PANCREATIC ISLET β CELL IN VITRO.

Authors:  John Z Q Luo; Joseph W Kim; LuGuang Luo
Journal:  Eur J Pharm Med Res       Date:  2016-01

5.  Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus.

Authors:  Weidong Xie; Yunan Zhao; Yaou Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-17       Impact factor: 2.629

6.  Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study.

Authors:  Ji Won Yoon; Seon Mee Kang; Jason L Vassy; Hayley Shin; Yun Hee Lee; Hwa Young Ahn; Sung Hee Choi; Kyong Soo Park; Hak Chul Jang; Soo Lim
Journal:  J Diabetes Investig       Date:  2012-06-06       Impact factor: 4.232

7.  Cytoprotective effects of ginsenoside Rd on apoptosis-associated cell death in the isolated human pancreatic islets.

Authors:  Maryam Kaviani; Somayeh Keshtkar; Negar Azarpira; Mahdokht Hossein Aghdaei; Bita Geramizadeh; Mohammad Hossein Karimi; Ramin Yaghobi; Elaheh Esfandiari; Alireza Shamsaeefar; Saman Nikeghbalian; Ismail H Al-Abdullah
Journal:  EXCLI J       Date:  2019-08-22       Impact factor: 4.068

8.  Ginseng and diabetes: the evidences from in vitro, animal and human studies.

Authors:  Hai-Dan Yuan; Jung Tae Kim; Sung Hoon Kim; Sung Hyun Chung
Journal:  J Ginseng Res       Date:  2012-01       Impact factor: 6.060

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.